Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib

Calcified Tissue International

Volumn 79, Issue 4, 2006, Pages 255-261

  Allen, M R ^a   Follet, H ^a   Khurana, M ^a   Sato, M ^a,b   Burr, D B ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Indiana University Purdue University Indianapolis   (United States)

Author keywords

Alendronate; Bisphosphonate; Periosteal; Raloxifene; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; RALOXIFENE; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BONE DEVELOPMENT; CONTROLLED STUDY; DOG; FEMALE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL;

EID: 33750549653     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-006-0031-5     Document Type: Article

References (54)

1. Fisher JE, Rodan GA, Reszka AA (2000) In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793-4796
2. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138
3. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
4. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589
5. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanisms of action of bisphosphonates. Bone 24:73S-79S
6. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
7. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, Papp AE de (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141-151
8. Delmas PD (2000) How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27:1-3
9. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G (1998) Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455-461
10. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105-4115
11. Schindeler A, Little DG (2005) Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 338:710-716
12. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374
13. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2696
14. Bikle D, Morey-Holton E, Doty S, Currier P, Tanner S, Halloran B (1994) Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res 9:1777-1787
15. Iwata K, Li J, Follet H, Phipps RJ, Burr DB (2006) Bisphosphonates suppress periosteal osteoblast activity independent of resorption in rat femur and tibia. Bone (Published online June 7, 2006)
16. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620
17. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531
18. Olivier S, Fillet M, Malaise M, Piette J, Bours V, Merville MP, Franchimont N (2005) Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem Pharmacol 69:891-901
19. Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, Raddatz D, Emons G, Hofbauer LC (2003) Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 88: 4206-4213
20. Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S (2002) The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30:368-376
21. Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP (2002) Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 9:320-328
22. 2 combine to improve the femoral neck strength of ovariectomized rats. Calcif Tissue Int 77:119-126
23. Ott SM, Oleksik A, Lu Y, Harper K, Lips P (2002) Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17:341-348
24. Frost HM (2004) The Utah Paradigm of Skeletal Physiology. Chapters 3 and 4. International Society of Musculoskeletal and Neuronal Interactions, Greece
25. Erben RG (1996) Trabecular and endocortical bone surfaces in the rat: modeling or remodeling? Anat Rec 246:39-46
26. Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625
27. Parfitt A, Drezner M, Glorieux F, Kanis J, Malluche H, Meunier P, Ott S, Recker R (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
28. Bord S, Horner A, Beavan S, Compston J (2001) Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab 86:2309-2314
29. Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson J-A, Ohlsson C (2000) Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci USA 97:5474-5479
30. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptor-β in bone remodeling in females but not in males. Bone 30:18-25
31. Lee K, Jessop H, Suswillo R, Zaman G, Lanyon L (2003) Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature 424:389
32. Saxon LK, Turner CH (2005) Estrogen receptor beta: the antimechanostat? Bone 36:185-192
33. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC (2004) Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell 15:1262-1272
34. Allen MR, Hock JM, Burr DB (2004) Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35:1003-1012
35. Orwoll E (2003) Toward an expanded understanding of the role of the periosteum in skeletal health. J Bone Miner Res 18:949-954
36. Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575-586
37. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR (2005) Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 20:1514-1524
38. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
39. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC 2nd, Hirsch LJ, Oppenheimer L, Thompson D (1997) Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277:1159-1164
40. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2004) Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:999-1005
41. Balena R, Markatos A, Seedor JG, Gentile M, Stark C, Peter CP, Rodan GA (1996) Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther 276:277-283
42. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586
43. Coxon F, Thompson K, Ebetino H, Rogers M (2006) Resorbing osteoclasts increase the availability of mineral-bound bisphosphonates to non-resorbing cells. Bone 38:S45
44. Gasser J, Ingold P, Rebmann A, Susa M, Green J (2006) Inhibition of FPP-synthase in osteoblasts may explain the blunting of bone anabolic response to PTH observed after chronic exposure of rats to bisphosphonates. Bone 38:S50
45. Bare S, Recker S, Recker R, Kimmel D (2005) Influence of alendronate on periosteal and endocortical bone formation in the ilium of osteoporotic women. J Bone Miner Res 20:SA414
46. Recker RR, Weinstein RS, Chesnut CH 3rd, Schimmer RC, Mahoney P, Hughes C, Bonvoisin B, Meunier PJ (2004) Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15:231-237
47. Alhlborg H, Johnell O, Turner C, Rannevik G, Karlsson M (2003) Bone loss and bone size after menopause. N Engl J Med 349:327-334
48. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME (2004) Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of Fosamax versus Evista Comparison Trial). Int J Intern Med 255:503-511
49. Allen MR, Iwata K, Sato M, Burr DB (2006) Raloxifene enhances vertebral mechanical properties independent of bone density. Bone (Published online June 30, 2006)
50. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565
51. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
52. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
53. Recker R, Masarachia P, Santora A, Howard T, Chavassieux P, Arlot M, Rodan G, Wehren L, Kimmel D (2005) Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21:185-194
54. Wolvekamp P (2002) The many faces of elbow dysplasia [abstract]. Proceedings from the 27th World Small Animal Veterinary Association Congress, Granada, Spain, October 2002